- Home
- TASK vs BEAM Comparison
TASK vs BEAM Comparison
Compare TASK & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TASK
- BEAM
- Stock Information
- Founded
- TASK 2008
- BEAM 2017
- Country
- TASK United States
- BEAM United States
- Employees
- TASK N/A
- BEAM N/A
- Industry
- TASK Retail: Computer Software & Peripheral Equipment
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TASK Technology
- BEAM Health Care
- Exchange
- TASK Nasdaq
- BEAM Nasdaq
- Market Cap
- TASK 1.5B
- BEAM 1.7B
- IPO Year
- TASK 2021
- BEAM 2020
- Fundamental
- Price
- TASK $17.39
- BEAM $16.86
- Analyst Decision
- TASK Buy
- BEAM Strong Buy
- Analyst Count
- TASK 5
- BEAM 10
- Target Price
- TASK $17.40
- BEAM $48.56
- AVG Volume (30 Days)
- TASK 234.9K
- BEAM 2.4M
- Earning Date
- TASK 08-07-2025
- BEAM 08-05-2025
- Dividend Yield
- TASK N/A
- BEAM N/A
- EPS Growth
- TASK 21.25
- BEAM N/A
- EPS
- TASK 0.67
- BEAM N/A
- Revenue
- TASK $1,101,465,000.00
- BEAM $60,272,000.00
- Revenue This Year
- TASK $19.40
- BEAM N/A
- Revenue Next Year
- TASK $11.62
- BEAM $17.95
- P/E Ratio
- TASK $25.96
- BEAM N/A
- Revenue Growth
- TASK 19.04
- BEAM N/A
- 52 Week Low
- TASK $10.57
- BEAM $13.53
- 52 Week High
- TASK $19.60
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- TASK 61.31
- BEAM 41.83
- Support Level
- TASK $17.19
- BEAM $16.29
- Resistance Level
- TASK $17.66
- BEAM $17.12
- Average True Range (ATR)
- TASK 0.19
- BEAM 0.80
- MACD
- TASK 0.02
- BEAM -0.04
- Stochastic Oscillator
- TASK 61.65
- BEAM 47.91
About TASK TaskUs Inc.
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to the world's most innovative companies, helping its clients represent, protect and grow their brands. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.